Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

Search life-sciences literature (45,105,671 articles, preprints and more)

Search results

1-25 of 80 results

Sort by:

Relevance ^{Relevance: This is determined based on a ranking of criteria including term frequency, rarity of term, recency of article, whether there is a Title or Author field match, etc.}

Times cited

Date

1 2 3 Next ...

Addressing urgent priorities in antibiotic development: insights from WHO 2023 antibacterial clinical pipeline analyses.
Melchiorri D, Rocke T, Alm RA, Cameron AM, Gigante V
Lancet Microbe, 100992, 22 Oct 2024
Cited by: 0 articles | PMID: 39454608
Add to export list Review
Multi-year analysis of the global preclinical antibacterial pipeline: trends and gaps.
Gigante V, Alm RA, Melchiorri D, Rocke T, Arias CA, Czaplewski L, Fernandes P, Franceschi F, Harbarth S, Kozlov R, Lienhardt C, Ohmagari N, Ogilvie LA, Paul M, Rex JH, Silver LL, Spigelman M, Sati H, Cameron AM
Antimicrob Agents Chemother, 68(8):e0053524, 15 Jul 2024
Cited by: 0 articles | PMID: 39007560 | PMCID: PMC11304740
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Reply to Kaye and Belley, "Third-Generation Cephalosporin-Resistant Enterobacterales Are Critical Priority Pathogens, Too!"
Butler MS, Gigante V, Sati H, Paulin S, Al-Sulaiman L, Rex JH, Fernandes P, Arias CA, Paul M, Thwaites GE, Czaplewski L, Alm RA, Lienhardt C, Spigelman M, Silver LL, Ohmagari N, Kozlov R, Harbarth S, Beyer P
Antimicrob Agents Chemother, 66(4):e0022322, 24 Mar 2022
Cited by: 1 article | PMID: 35323014 | PMCID: PMC9017292
Add to export list Free full text in Europe PMC
Antigenic landscapes on Staphylococcus aureus pore-forming toxins reveal insights into specificity and cross-neutralization.
Kailasan S, Kant R, Noonan-Shueh M, Kanipakala T, Liao G, Shulenin S, Leung DW, Alm RA, Adhikari RP, Amarasinghe GK, Gross ML, Aman MJ
MAbs, 14(1):2083467, 01 Jan 2022
Cited by: 4 articles | PMID: 35730685 | PMCID: PMC9225675
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed.
Butler MS, Gigante V, Sati H, Paulin S, Al-Sulaiman L, Rex JH, Fernandes P, Arias CA, Paul M, Thwaites GE, Czaplewski L, Alm RA, Lienhardt C, Spigelman M, Silver LL, Ohmagari N, Kozlov R, Harbarth S, Beyer P
Antimicrob Agents Chemother, 66(3):e0199121, 10 Jan 2022
Cited by: 80 articles | PMID: 35007139 | PMCID: PMC8923189
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
The CARB-X Portfolio of Nontraditional Antibacterial Products.
Duffy EM, Buurman ET, Chiang SL, Cohen NR, Uria-Nickelsen M, Alm RA
ACS Infect Dis, 7(8):2043-2049, 04 Aug 2021
Cited by: 9 articles | PMID: 34346202
Add to export list
A one health framework to estimate the cost of antimicrobial resistance.
Morel CM, Alm RA, Årdal C, Bandera A, Bruno GM, Carrara E, Colombo GL, de Kraker MEA, Essack S, Frost I, Gonzalez-Zorn B, Goossens H, Guardabassi L, Harbarth S, Jørgensen PS, Kanj SS, Kostyanev T, Laxminarayan R, Leonard F, [...] GAP-ON€ network
Antimicrob Resist Infect Control, 9(1):187, 26 Nov 2020
Cited by: 17 articles | PMID: 33243302 | PMCID: PMC7689633
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Narrow-Spectrum Antibacterial Agents-Benefits and Challenges.
Alm RA, Lahiri SD
Antibiotics (Basel), 9(7):E418, 17 Jul 2020
Cited by: 19 articles | PMID: 32708925 | PMCID: PMC7400354
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
A novel pre-clinical antibacterial pipeline database.
Paulin S, Alm RA, Beyer P
PLoS One, 15(7):e0236604, 28 Jul 2020
Cited by: 5 articles | PMID: 32722726 | PMCID: PMC7386594
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Innovation in Antimicrobial Resistance: The CARB-X Perspective.
Alm RA, Gallant K
ACS Infect Dis, 6(6):1317-1322, 01 Jun 2020
Cited by: 21 articles | PMID: 32202756
Add to export list
Population health model for pharmacist assessment and independent prescribing of statins in an ambulatory care setting.
Haby HE, Alm RA, Corona AR, Hall AC
J Am Pharm Assoc (2003), 60(1):130-137, 02 Nov 2019
Cited by: 4 articles | PMID: 31690511
Add to export list
Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model.
Singh R, Almutairi M, Alm RA, Lahiri SD, San Martin M, Chen A, Ambler JE
J Antimicrob Chemother, 72(10):2796-2803, 01 Oct 2017
Cited by: 13 articles | PMID: 29091195
Add to export list
Structural and sequence analysis of class A β-lactamases with respect to avibactam inhibition: impact of Ω-loop variations.
Lahiri SD, Bradford PA, Nichols WW, Alm RA
J Antimicrob Chemother, 71(10):2848-2855, 07 Jul 2016
Cited by: 19 articles | PMID: 27402011
Add to export list
Identification of non-PBP2a resistance mechanisms in Staphylococcus aureus after serial passage with ceftaroline: involvement of other PBPs.
Lahiri SD, Alm RA
J Antimicrob Chemother, 71(11):3050-3057, 05 Aug 2016
Cited by: 16 articles | PMID: 27494915
Add to export list
Identification of Novel VEB β-Lactamase Enzymes and Their Impact on Avibactam Inhibition.
Lahiri SD, Alm RA
Antimicrob Agents Chemother, 60(5):3183-3186, 22 Apr 2016
Cited by: 20 articles | PMID: 26926646 | PMCID: PMC4862473
Add to export list Free full text in Europe PMC
Multi-center and multi-method evaluation of in vitro activities of ceftaroline against S. aureus.
Koeth LM, Apfalter P, Becker K, Gesu G, Martínez-Martínez L, Lahiri SD, Alm RA, Ambler J, Iaconis J
Diagn Microbiol Infect Dis, 85(4):452-458, 08 May 2016
Cited by: 4 articles | PMID: 27233426
Add to export list
Ceftaroline Activity against mecC-Containing Staphylococcus aureus.
Lahiri SD, Alm RA
J Clin Microbiol, 53(9):3102-3103, 01 Jul 2015
Cited by: 1 article | PMID: 26135876 | PMCID: PMC4540908
Add to export list Free full text in Europe PMC
Molecular characterization of MRSA isolates bracketing the current EUCAST ceftaroline-susceptible breakpoint for Staphylococcus aureus: the role of PBP2a in the activity of ceftaroline.
Lahiri SD, McLaughlin RE, Whiteaker JD, Ambler JE, Alm RA
J Antimicrob Chemother, 70(9):2488-2498, 04 Jun 2015
Cited by: 27 articles | PMID: 26045529
Add to export list
Multidrug-Resistant Neisseria gonorrhoeae Isolates from Nanjing, China, Are Sensitive to Killing by a Novel DNA Gyrase Inhibitor, ETX0914 (AZD0914).
Su XH, Wang BX, Le WJ, Liu YR, Wan C, Li S, Alm RA, Mueller JP, Rice PA
Antimicrob Agents Chemother, 60(1):621-623, 19 Oct 2015
Cited by: 12 articles | PMID: 26482313 | PMCID: PMC4704236
Add to export list Free full text in Europe PMC
In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolated in 2012 from Asia-Pacific Countries as Part of the AWARE Surveillance Program.
Biedenbach DJ, Alm RA, Lahiri SD, Reiszner E, Hoban DJ, Sahm DF, Bouchillon SK, Ambler JE
Antimicrob Agents Chemother, 60(1):343-347, 26 Oct 2015
Cited by: 27 articles | PMID: 26503659 | PMCID: PMC4704164
Add to export list Free full text in Europe PMC
In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolates Collected in 2012 from Latin American Countries as Part of the AWARE Surveillance Program.
Biedenbach DJ, Hoban DJ, Reiszner E, Lahiri SD, Alm RA, Sahm DF, Bouchillon SK, Ambler JE
Antimicrob Agents Chemother, 59(12):7873-7877, 28 Sep 2015
Cited by: 12 articles | PMID: 26416860 | PMCID: PMC4649166
Add to export list Free full text in Europe PMC
Corrigendum: Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases.
Basarab GS, Kern GH, McNulty J, Mueller JP, Lawrence K, Vishwanathan K, Alm RA, Barvian K, Doig P, Galullo V, Gardner H, Gowravaram M, Huband M, Kimzey A, Morningstar M, Kutschke A, Lahiri SD, Perros M, Singh R, [...] Newman JV
Sci Rep, 5:14157, 18 Sep 2015
Cited by: 0 articles | PMID: 26383116 | PMCID: PMC4585652
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases.
Basarab GS, Kern GH, McNulty J, Mueller JP, Lawrence K, Vishwanathan K, Alm RA, Barvian K, Doig P, Galullo V, Gardner H, Gowravaram M, Huband M, Kimzey A, Morningstar M, Kutschke A, Lahiri SD, Perros M, Singh R, [...] Newman JV
Sci Rep, 5:11827, 14 Jul 2015
Cited by: 56 articles | PMID: 26168713 | PMCID: PMC4501059
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Potential of Staphylococcus aureus isolates carrying different PBP2a alleles to develop resistance to ceftaroline.
Lahiri SD, Alm RA
J Antimicrob Chemother, 71(1):34-40, 19 Oct 2015
Cited by: 12 articles | PMID: 26483514
Add to export list
Insights into the mechanism of inhibition of novel bacterial topoisomerase inhibitors from characterization of resistant mutants of Staphylococcus aureus.
Lahiri SD, Kutschke A, McCormack K, Alm RA
Antimicrob Agents Chemother, 59(9):5278-5287, 15 Jun 2015
Cited by: 18 articles | PMID: 26077256 | PMCID: PMC4538526
Add to export list Free full text in Europe PMC

1-25 of 80 results

1 2 3 Next ...

Search life-sciences literature (45,105,671 articles, preprints and more)

Search results

Addressing urgent priorities in antibiotic development: insights from WHO 2023 antibacterial clinical pipeline analyses.

Multi-year analysis of the global preclinical antibacterial pipeline: trends and gaps.

Reply to Kaye and Belley, "Third-Generation Cephalosporin-Resistant Enterobacterales Are Critical Priority Pathogens, Too!"

Antigenic landscapes on Staphylococcus aureus pore-forming toxins reveal insights into specificity and cross-neutralization.

Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed.

The CARB-X Portfolio of Nontraditional Antibacterial Products.

A one health framework to estimate the cost of antimicrobial resistance.

Narrow-Spectrum Antibacterial Agents-Benefits and Challenges.

A novel pre-clinical antibacterial pipeline database.

Innovation in Antimicrobial Resistance: The CARB-X Perspective.

Population health model for pharmacist assessment and independent prescribing of statins in an ambulatory care setting.

Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model.

Structural and sequence analysis of class A β-lactamases with respect to avibactam inhibition: impact of Ω-loop variations.

Identification of non-PBP2a resistance mechanisms in Staphylococcus aureus after serial passage with ceftaroline: involvement of other PBPs.

Identification of Novel VEB β-Lactamase Enzymes and Their Impact on Avibactam Inhibition.

Multi-center and multi-method evaluation of in vitro activities of ceftaroline against S. aureus.

Ceftaroline Activity against mecC-Containing Staphylococcus aureus.

Molecular characterization of MRSA isolates bracketing the current EUCAST ceftaroline-susceptible breakpoint for Staphylococcus aureus: the role of PBP2a in the activity of ceftaroline.

Multidrug-Resistant Neisseria gonorrhoeae Isolates from Nanjing, China, Are Sensitive to Killing by a Novel DNA Gyrase Inhibitor, ETX0914 (AZD0914).

In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolated in 2012 from Asia-Pacific Countries as Part of the AWARE Surveillance Program.

In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolates Collected in 2012 from Latin American Countries as Part of the AWARE Surveillance Program.

Corrigendum: Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases.

Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases.

Potential of Staphylococcus aureus isolates carrying different PBP2a alleles to develop resistance to ceftaroline.

Insights into the mechanism of inhibition of novel bacterial topoisomerase inhibitors from characterization of resistant mutants of Staphylococcus aureus.

Partnerships & funding